Eravacycline is a fully synthetic fluorocycline, structurally related to tigecycline but engineered with modifications that broaden its spectrum and improve its pharmacokinetic profile. It works by binding to the 30S ribosomal subunit, blocking protein synthesis in susceptible bacteria. Approved for use against complicated intra-abdominal infections, it has attracted growing interest as a potential salvage option for multidrug-resistant Gram-negative pathogens, including carbapenem-resistant Enterobacterales and, increasingly, S. maltophilia. Yet until now, clinical evidence evaluating eravacycline specifically against S. maltophilia has remained limited worldwide, leaving clinicians without solid guidance on whether the drug actually works in real patients.

The new study, led by researchers at Peking Union Medical College Hospital and published in BMC Infectious Diseases, set out to fill that gap. It analysed 103 adult patients who were treated with eravacycline-containing regimens for at least 72 hours for confirmed S. maltophilia infections between August 2023 and August 2024. The researchers tracked a battery of outcomes: overall clinical effectiveness at the end of treatment, clinical effectiveness 30 days after treatment ended, patient prognosis at discharge, microbiological clearance, and adverse events. This retrospective, multicentre design drew on de-identified medical records from multiple Chinese hospitals, giving the findings a breadth that single-centre reports cannot match.

The headline result is striking. The overall clinical effectiveness rate was 90.3 percent, or 93 out of 103 patients, at the end of treatment. Thirty days after treatment ended, the rate remained essentially stable at 88.3 percent, or 91 out of 103 patients. Furthermore, 88.3 percent of patients showed clinical improvement by the time of discharge. These figures suggest that eravacycline-containing regimens not only work in the short term but also produce durable results that hold up well beyond the treatment window, a critical consideration for infections that can relapse or persist in vulnerable hosts.

When the researchers broke down the results by infection type, the picture remained consistently favourable. Isolated pneumonia was the most common presentation, affecting 71 of 103 patients, or 68.9 percent of the cohort. Pneumonia with concomitant infection accounted for 21 patients, or 20.4 percent, while isolated extrapulmonary infection affected 11 patients, or 10.7 percent. At the end of treatment, clinical effectiveness rates were 87.3 percent for isolated pneumonia, 95.2 percent for pneumonia with concomitant infection, and 90.9 percent for isolated extrapulmonary infection. By day 30 after treatment ended, these rates remained stable across the respective subgroups, indicating that eravacycline performed well regardless of whether the infection was confined to the lungs or had spread elsewhere.

Microbiological clearance, a key secondary outcome, added further weight to the findings. Among 61 patients with evaluable follow-up cultures, S. maltophilia was cleared in 93.4 percent of cases, or 57 out of 61 patients. This high rate of bacterial eradication suggests that eravacycline-containing regimens are not merely masking symptoms but are genuinely eliminating the pathogen from infected sites. For a bacterium that can persist in biofilms and colonise immunocompromised hosts for extended periods, this level of microbiological efficacy is a meaningful signal.

Safety is often the Achilles heel of new antibiotics, but eravacycline fared well on this front too. Adverse events were minimal, affecting only 3 of 103 patients, or 2.9 percent of the cohort, and none were severe. This favourable safety profile is consistent with what has been observed in phase II and phase III trials of eravacycline for other indications, and it reinforces the drug’s potential as a tolerable option for patients who may already be dealing with a heavy burden of comorbidities and concurrent medications.

The authors are careful to temper enthusiasm with appropriate scientific caution. Because this was a retrospective observational study, baseline selection bias is an inherent limitation. Clinicians may have preferentially prescribed eravacycline to patients they believed would respond well, or to those who had failed other therapies, and these choices can skew the apparent effectiveness in either direction. The observed effectiveness, the researchers emphasise, must be interpreted cautiously for this reason. Without a randomised controlled trial, it is impossible to fully disentangle the drug’s true effect from the effects of patient selection and concurrent care.

Nevertheless, the study represents a significant step forward in the clinical evidence base for eravacycline against S. maltophilia. As multidrug resistance continues to erode the utility of older antibiotics, and as S. maltophilia infections become increasingly common in intensive care settings, the need for effective alternatives has never been greater. Eravacycline, with its broad spectrum, favourable pharmacokinetics, and now demonstrated real-world effectiveness, emerges as a potential alternative or salvage option for clinicians facing this difficult pathogen. The findings from this Chinese multicentre cohort provide a foundation upon which future prospective studies and randomised trials can build, ultimately clarifying the drug’s role in the standard of care for S. maltophilia infections worldwide.

Subject of Research: Clinical outcomes of eravacycline in Stenotrophomonas maltophilia infections

Article Title: Clinical outcomes of Eravacycline in patients with Stenotrophomonas maltophilia infections: a multicentre observational study in China

Article References: Zhai, X., Li, Y., Zhou, M., Xu, Y., & Yi, Q. (2026). Clinical outcomes of Eravacycline in patients with Stenotrophomonas maltophilia infections: a multicentre observational study in China. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14302-6

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14302-6

Keywords: Stenotrophomonas maltophilia, Eravacycline, Antibiotic resistance, Clinical outcomes, Multidrug resistance, Observational study, BMC Infectious Diseases, Clinical, outcomes, patients, Stenotrophomonas, maltophilia

The study, published in the journal Advanced Biotechnology, is the first to report that the gut microbiome of Zophobas atratus larvae can degrade disposable face masks. The researchers, led by Chunlan Mao of the Northwest Institute of Eco-Environment and Resources at the Chinese Academy of Sciences together with colleagues at Lanzhou University, measured a consumption rate of 60 milligrams of dry mask material per day for every 50 larvae, a figure they describe as a high degrading rate for the middle layer of the mask. That middle layer, the melt-blown polypropylene core that provides most of a mask’s filtration, turned out to be the larvae’s favorite part of the mask by far.

The experimental design was straightforward but meticulous. Larvae averaging about 27 milligrams each were placed in food-grade containers at a density of roughly half a larva per square centimeter and kept in a constant-temperature chamber at 25 degrees Celsius and 65 percent humidity. Five groups were compared: starved larvae, larvae fed wheat bran, and larvae fed separately with the outer, middle, and inner layers of a commercially purchased disposable mask. Over 12 days, the larvae consumed 356.7 milligrams of the middle layer per 50 animals, compared with only 16.7 milligrams of the outer layer, while the inner layer actually gained mass because the insects’ fecal material adhered strongly to its surface.

Survival rates told an equally interesting story. Larvae fed the middle layer survived at 95.3 percent, nearly matching the 96.7 percent survival of larvae eating their normal wheat bran diet, which suggests the mask material was genuinely digested and utilized rather than merely chewed and discarded. Larvae fed the outer and inner layers also maintained survival rates of 79 and 85 percent respectively. Body weight told a different story: bran-fed larvae gained 80.5 milligrams collectively, while mask-fed groups lost weight, a consequence the researchers attribute to the fact that polypropylene contains only hydrogen and carbon and lacks the nitrogen and other nutrients insects need for growth.

To confirm that chemical degradation, not just mechanical fragmentation, was taking place, the team turned to a battery of spectroscopic and thermal techniques. Fourier-transform infrared spectroscopy of the frass from mask-fed larvae revealed a distinct new peak near 1700 reciprocal centimeters, the signature of carbonyl groups formed by oxidation of the polymer backbone. The spectra also showed broadened absorption between 3000 and 3500 reciprocal centimeters associated with hydroxyl stretching, further evidence that oxygen had been incorporated into the plastic. Thermogravimetric analysis showed that frass from mask-fed larvae decomposed differently from intact mask material, indicating the presence of new organic matter rather than simply unchanged polypropylene fragments.

Perhaps the most striking physical evidence came from water contact angle measurements, which quantify how hydrophobic a surface is. The intact mask measured a contact angle of about 136 degrees, typical of a highly water-repellent plastic. The frass of mask-fed larvae measured only 73.55 degrees, a dramatic drop in hydrophobicity. This matters because hydrophobic polymer surfaces resist the adsorption of polymer-degrading enzymes; making the surface more wettable exposes the carbon-carbon bonds of the polypropylene chain to enzymatic attack. The decrease in hydrophobicity is therefore both a marker of biodegradation and a mechanism that enables it to continue.

The decisive proof that gut microbes, rather than the larvae’s own digestive machinery, were doing the work came from an antibiotic suppression experiment. The researchers fed larvae wheat bran treated with gentamicin sulfate for ten days, reducing their gut bacterial counts by two orders of magnitude, then offered them masks. The result was stark: survival fell from 95.3 percent to 48.3 percent, mask consumption dropped significantly, and the frass no longer showed the carbonyl and hydroxyl peaks that signal oxidation. Larvae stripped of their gut microbiome simply lost the ability to depolymerize the mask, confirming that degradation is gut microbiome-dependent, a pattern consistent with earlier work on polystyrene and polyethylene breakdown in the same species.

Sequencing of the 16S rRNA gene revealed how the microbial community reorganized itself in response to the plastic diet. Proteobacteria, which made up 57.57 percent of the gut community in bran-fed larvae, rose to between 79 and 85 percent in larvae eating any of the three mask layers, while Firmicutes declined sharply. At the genus level, the researchers identified Hafnia, Corynebacterium, Xenorhabdus, and Providencia as the functional bacteria most strongly associated with mask degradation, with Hafnia and Corynebacterium showing particularly high abundance. Several of these genera have prior records in plastic degradation: Hafnia has documented plastic-degrading capability, and Corynebacterium and Pseudomonas have been linked to the breakdown of synthetic polymers such as polyethylene and polystyrene.

Untargeted metabolomics using liquid chromatography-mass spectrometry added a metabolic dimension to the picture. Compared with bran-fed larvae, mask-fed larvae showed 46 significantly upregulated and 59 downregulated metabolites, and pathway analysis pointed to the cytochrome P450 system, steroid hormone biosynthesis, and biotin metabolism as the pathways most disrupted by the mask diet. Predictive analysis of functional genes using PICRUSt2 found that genes for cytochrome P450 enzymes, esterases, and peroxidases were significantly enriched in mask-fed larvae, with esterases and peroxidases reaching statistical significance. The authors suggest that reactive oxygen species generated in the gut micro-environment, together with these oxidative enzyme systems, coordinate the initial oxidation of the otherwise inert polymer, though they caution that mask ingestion appears to impose metabolic stress on the larvae, and that the long-term costs of a plastic-only diet remain unknown.

Finally, the team isolated seven bacterial strains from the guts of mask-fed larvae and screened them for biofilm formation on mask membranes. The most successful colonizer, identified as Stenotrophomonas sp. strain M212, formed dense biofilms and etched pits and cavities into the mask surface under scanning electron microscopy, while the uninoculated control remained smooth. X-ray photoelectron spectroscopy showed that the oxygen content of the mask surface rose from 2.18 percent to 5.82 percent after exposure to the strain, and infrared spectroscopy detected new carbon-oxygen and hydroxyl stretches, hallmarks of oxidative biodegradation. The strain also reduced the hydrophobicity of the mask surface, priming it for further attack. Together, the larval feeding trials, the antibiotic suppression test, the multi-omics characterization, and the isolation of a degrading strain close the loop: the gut microbiome of Zophobas atratus, and Stenotrophomonas sp. M212 in particular, can genuinely oxidize and depolymerize disposable face masks. The researchers emphasize that important questions remain, including whether larvae can sustain normal growth on masks alone, what individual roles each functional bacterium plays, and how in vitro degradation might be optimized, but the work opens a biologically grounded path toward treating one of the pandemic’s most visible legacies of plastic pollution.

Subject of Research: Biodegradation of disposable polypropylene face masks by the gut microbiome of Zophobas atratus larvae

Article Title: Responses of gut microbial community and metabolic function to disposable face mask of Zophobas atratus larvae

Article References: Mao, C., Zhang, K., Tursunay, M., Ji, J., & Li, X. (2026). Responses of gut microbial community and metabolic function to disposable face mask of Zophobas atratus larvae. Advanced Biotechnology, 4(1), Article 1. https://doi.org/10.1007/s44307-025-00092-6

Image Credits: AI Generated

DOI: 10.1007/s44307-025-00092-6

Keywords: superworms, Zophobas atratus, disposable face masks, polypropylene, biodegradation, gut microbiome, Hafnia, Corynebacterium, Stenotrophomonas, cytochrome P450, microplastics, plastic pollution